Clinical Trials

LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05622591 2024-08-07

Pediatric AML

Recurrence, Leukemia, Myeloid, Acute

NCT06362031 2024-04-12

A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review

Withdrawn

Neoplasms, Leukemia, Myeloid, Acute

NCT05367401 2024-04-11

A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT05943314 2023-11-02

Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid Leukemia

Phase NA Withdrawn

Leukemia, Myeloid, Acute

NCT05456269 2023-10-03

BISECT

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03932318 2023-07-20

Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

Leukemia, Myeloid, Acute

NCT04896112 2023-06-18

A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia

Polycythemia Vera, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT03904069 2023-06-12

Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML

Neoplasms, Leukemia, Myeloid, Acute

NCT04230564 2023-06-07

Acute Myeloid Leukemia Real World Treatment Patterns

Withdrawn

Leukemia, Myeloid, Acute

NCT05246384 2022-10-31

Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05279859 2022-06-15

HERKULES-4

Recurrence, Leukemia, Myeloid, Acute

NCT04464889 2021-10-08

HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT04395092 2021-06-22

Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02487459 2020-10-05

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03059615 2020-07-31

A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04106076 2020-07-14

Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

NCT02923986 2020-05-28

Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT03760445 2020-01-09

HDM201 Added to CT in R/R or Newly Diagnosed AML

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT03612739 2019-10-29

EPITHINK

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02826642 2019-04-10

A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

NCT03187691 2019-03-08

Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02269579 2018-03-14

Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02856178 2018-02-15

SAFEGUARD

Leukemia, Myeloid, Acute, Invasive Pulmonary Aspergillosis

NCT03036046 2018-02-15

SAFEGUARDFP

Leukemia, Myeloid, Acute

NCT02520102 2017-04-20

Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia

Leukemia, Myeloid, Acute

NCT02722135 2017-01-27

A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed

Leukemia, Myeloid, Acute

NCT01520805 2016-12-29

Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT02303782 2016-09-01

A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)

Leukemia, Myeloid, Acute

NCT00943553 2015-04-13

A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Leukemia, Myeloid, Acute

NCT00081055 2014-12-04

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02238522 2014-11-13

Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Prolymphocytic, B-Cell

NCT00967512 2014-09-18

Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course

Leukemia, Myeloid, Acute

NCT00396968 2014-02-11

AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01478074 2014-01-03

ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia

Leukemia, Leukemia, Myeloid, Acute

NCT00297921 2013-11-06

A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy